Actor Eric Dane died on Thursday, February 19, 2026, after a “courageous battle” with amyotrophic lateral sclerosis (ALS), his official Instagram account announced. “He spent his final days surrounded by dear friends, his devoted wife, Rebecca, and his two beautiful daughters, Billie and Georgia, who were the center of his world,” the post read.
Dane, 53, had publicly shared his ALS diagnosis 10 months earlier and became an outspoken advocate for awareness and research. He partnered with I AM ALS and its Push for Progress initiative to raise funds for research and expand access to promising treatments. He also lobbied for extension of the Accelerating Access to Critical Therapies for ALS Act — a law passed in 2021 that provided five years of research funding and early access to ALS treatments and is set to expire in 2026, according to reporting from CNN.
Best known for playing Dr. Mark “McSteamy” Sloan on Grey’s Anatomy and Cal Jacobs on Euphoria, Dane told People after his diagnosis, “I feel fortunate that I am able to continue working and am looking forward to returning to the set of Euphoria next week.” His family’s announcement noted, however, that “[h]is illness progressed far more quickly than anyone could have imagined.”
Rab Nawaz Khan, MD, a board-certified neurologist and consultant at MyMSTeam, told Healthline that ALS is a progressive disease that damages motor neurons — the nerve cells controlling voluntary movement. Often called Lou Gehrig’s disease, ALS commonly begins with focal weakness such as hand clumsiness, foot drop, tripping, trouble with buttons, or changes in speech clarity. Many patients also notice muscle cramps, twitching, and thinning in affected areas.
As ALS advances, weakness can spread to affect walking, arm function, speech, and swallowing. Eventually, breathing muscles weaken, leading to symptoms like poor sleep, morning headaches, and shortness of breath with activity. Sensation is usually preserved, so numbness and tingling are not typical, and a subset of patients may experience changes in thinking or behavior.
The National Institute of Neurological Disorders and Stroke notes ALS can occur at any age but is more common between ages 55 and 75, with younger men more likely than younger women to develop it; women’s rates catch up with age. Non-Hispanic white people are more likely to develop ALS, and there is a poorly understood association between military service and the disease. About 10% of ALS cases are linked to a genetic mutation.
There is no cure for ALS, but treatments can slow progression for some patients and improve comfort and function. Disease-targeted medications include riluzole and edaravone; a gene-targeted therapy exists for an inherited form related to the SOD1 mutation. Khan emphasized that multidisciplinary ALS care — addressing breathing, nutrition, mobility, and communication early — often has the biggest impact. Noninvasive ventilation can improve sleep, energy, and quality of life as breathing weakens, and cough-assist devices aid secretion clearance. Nutrition support, speech therapy, communication devices, physical and occupational therapy, and symptom-directed medications for spasticity, drooling, cramps, mood issues, or pseudobulbar affect can significantly reduce daily burden.
Research into ALS treatments is ongoing, and Dane’s advocacy helped draw attention and resources to the cause. Though the disease ultimately claimed his life, his efforts to raise awareness and support research may accelerate progress for others living with ALS.
